Complexa, a drug developer using synthetic fatty acids to treat chronic and acute kidney disease, has raised $13 million in a Series B financing round, according to a company statement. The new funding comes as it prepares to file an IND for an oral formulation for chronic kidney disease and will help advance its Phase 1 stage treatment for contrast-induced nephropathy, a complication from medical imaging.
Chronic kidney disease affects an estimated 20 million people, according to data from the Centers for Disease Control.
Complexa developed a synthetic form of nitro fatty acids that aid in shutting down harmful inflammatory pathways and activate the body’s protective mechanisms against inflammation.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
JAFCO Life Science Investment led the Series B round and current investors also took part. Among its investors are Scientific Health Development, Wistar Morris Foundation and UpStart.
Its drug, CXA-10, will be used in an IV form to treat acute kidney injuries caused by an inflammatory reaction to dye injections from medical imaging. It is associated with a higher risk of in-hospital and 1-year mortality, even in patients who do not need dialysis. It began Phase 1 trials earlier this month to assess safety and pharmacokinetics.
The use of intravenous contrast to enhance computed tomography imaging has increased in recent years, according to a paper published in The Clinical Journal of the American Society of Nephrology. So the number of contrast-induced nephropathy cases could increase. The biotechnology company sees applications for its drug beyond these kidney conditions, including neurodegenerative and fibrotic-related therapeutic areas.